Advancing Efruxifermin (EFX) for MASH
Our flagship EFX program is designed to be a differentiated, potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH).
Ongoing Clinical Studies
We have multiple ongoing clinical trials to evaluate our investigational drug, EFX, as a treatment for MASH.
